Effect of fluvoxamine vs placebo on clinical deterioration in outpatients with symptomatic COVID-19

(JAMA Network) This randomized trial compares the effects of fluvoxamine, a selective serotonin reuptake inhibitor with immunomodulatory effects, versus placebo on a composite of dyspnea or pneumonia and oxygen desaturation among adult outpatients with polymerase chain reaction-confirmed mild COVID-19 illness.